- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mereo BioPharma Group PLC ADR (MREO)
Mereo BioPharma Group PLC ADR stock price live, this page displays NASDAQ MREO stock exchange data. View the MREO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mereo BioPharma Group PLC ADR real time stock price chart below.
What Is the Mereo BioPharma Group PLC ADR Stock Price Today?
The Mereo BioPharma Group PLC ADR stock price today is 0.298.
What Is the Stock Symbol for Mereo BioPharma Group PLC ADR?
The stock ticker symbol for Mereo BioPharma Group PLC ADR is MREO.
Is MREO the Same as $MREO?
$MREO is a common way to refer to the Mereo BioPharma Group PLC ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Mereo BioPharma Group PLC ADR Trade On?
Mereo BioPharma Group PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Mereo BioPharma Group PLC ADR a Good Stock to Buy?
Determining whether Mereo BioPharma Group PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Mereo BioPharma Group PLC ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MREO quote. (ISIN: US5894921072)
What Is the Mereo BioPharma Group PLC ADR Stock Price Today?
The Mereo BioPharma Group PLC ADR stock price today is 0.298.
What Is the Stock Symbol for Mereo BioPharma Group PLC ADR?
The stock ticker symbol for Mereo BioPharma Group PLC ADR is MREO.
Is MREO the Same as $MREO?
$MREO is a common way to refer to the Mereo BioPharma Group PLC ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Mereo BioPharma Group PLC ADR Trade On?
Mereo BioPharma Group PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Mereo BioPharma Group PLC ADR a Good Stock to Buy?
Determining whether Mereo BioPharma Group PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Mereo BioPharma Group PLC ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MREO quote. (ISIN: US5894921072)
0.298
+0.005(+1.53%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.290
0.306
52 wk Range
0.200
2.370
MREO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2900.306
52 wk Range
0.2002.370
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MREO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
2.017
Upside
+576.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 8K MEREO BIOPHARMA GROUP PLC For: 11 August- Investing.com
- Form 8K MEREO BIOPHARMA GROUP PLC For: 19 August
- Investing.com
- Form 8K MEREO BIOPHARMA GROUP PLC For: 19 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
2 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2.017
(+576.91% Upside)
Mereo BioPharma Group PLC ADR SWOT Analysis
Investment Outlook | Analyst price targets range from $5.97 to $10.00, reflecting optimism in Mereo's pipeline and financial stability through 2027 |
Market Potential | Delve into Mereo's commercial strategy and market opportunity, with analyst projections exceeding $500 million in EU revenue by mid-2030s |
Clinical Milestones | Anticipate key trial results, including setrusumab's Phase 3 interim analysis in 2025, potentially transforming treatment for brittle bone disorde |
Pipeline Promise | Explore Mereo BioPharma's late-stage candidates for rare diseases, with setrusumab for osteogenesis imperfecta and alvelestat for AATD lung disease |
Earnings
Latest Release
Aug 11, 2026
EPS / Forecast
-0.01 / -0.01
Revenue / Forecast
-- / 2.33M
Compare MREO to Peers and Sector
Metrics to compare | MREO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMREOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −2.3x | −0.3x | |
PEG Ratio | −0.04 | 0.05 | 0.00 | |
Price / Book | 1.6x | 8.6x | 2.6x | |
Price / LTM Sales | - | 5.3x | 3.1x | |
Upside (Analyst Target) | - | 86.7% | 47.6% | |
Fair Value Upside | Unlock | 10.0% | 5.6% | Unlock |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Mereo BioPharma ADR (MREO) Stock Price Today?
The Mereo BioPharma ADR stock price today is 0.298 USD.
What Stock Exchange Does Mereo BioPharma ADR Trade On?
Mereo BioPharma ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Mereo BioPharma ADR?
The stock symbol for Mereo BioPharma ADR is "MREO."
What Is the Mereo BioPharma ADR Market Cap?
As of today, Mereo BioPharma ADR market cap is 46.840M USD.
What Is Mereo BioPharma ADR's Earnings Per Share (TTM)?
The Mereo BioPharma ADR EPS (TTM) is -0.175.
When Is the Next Mereo BioPharma ADR Earnings Date?
Mereo BioPharma ADR will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is MREO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Mereo BioPharma ADR Stock Split?
Mereo BioPharma ADR has split 0 times.
How Many Employees Does Mereo BioPharma ADR Have?
Mereo BioPharma ADR has 39 employees.
What is the current trading status of Mereo BioPharma ADR (MREO)?
As of Aug 21, 2026, Mereo BioPharma ADR (MREO) is trading at a price of 0.298 USD, with a previous close of 0.293 USD. The stock has fluctuated within a day range of 0.290 USD to 0.306 USD, while its 52-week range spans from 0.200 USD to 2.370 USD.
What Is Mereo BioPharma ADR (MREO) Price Target According to Analysts?
The average 12-month price target for Mereo BioPharma ADR is 2.017 USD, with a high estimate of 3.03208191 USD and a low estimate of 1.01023891 USD. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +576.91% Upside potential.
What Is the MREO Premarket Price?
MREO's last pre-market stock price is 0.306 USD. The pre-market share volume is 30,340.000, and the stock has decreased by 0.013, or 4.440%.
What Is the MREO After Hours Price?
MREO's last after hours stock price is 0.294 USD, the stock has decreased by 0.001, or 0.340%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.